Last reviewed · How we verify
MPV-A Vaccine Group
MPV-A is a multi-pathogen vaccine designed to provide immunological protection against multiple viral pathogens through stimulation of adaptive immune responses.
MPV-A is a multi-pathogen vaccine designed to provide immunological protection against multiple viral pathogens through stimulation of adaptive immune responses. Used for Prevention of multiple viral infections (specific pathogens not publicly detailed).
At a glance
| Generic name | MPV-A Vaccine Group |
|---|---|
| Also known as | Group A Meningococcal Polysaccharide vaccine |
| Sponsor | Beijing Minhai Biotechnology Co., Ltd |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine works by presenting antigens from multiple pathogens to the immune system, triggering both humoral (antibody-mediated) and cellular immune responses. This approach aims to generate protective immunity against the targeted pathogens, potentially reducing infection rates or disease severity in vaccinated populations.
Approved indications
- Prevention of multiple viral infections (specific pathogens not publicly detailed)
Common side effects
- Injection site reactions
- Fever
- Myalgia
Key clinical trials
- A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years (PHASE4)
- Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MPV-A Vaccine Group CI brief — competitive landscape report
- MPV-A Vaccine Group updates RSS · CI watch RSS
- Beijing Minhai Biotechnology Co., Ltd portfolio CI